沙库巴曲缬沙坦对慢性心力衰竭患者血心室重塑相关指标及心功能的影响

  目的  通过测定慢性心力衰竭(CHF)患者应用沙库巴曲缬沙坦前后的血亲环素A(CyPA)、半乳糖凝集素3(Galectin-3)、基质金属蛋白酶2(MMP-2)、MMP-9、N端-脑钠肽(NT-proBNP)水平，探讨沙库巴曲缬沙坦对慢性心衰患者血心室重塑相关指标及心功能的影响。  方法  选取2018年12月—2022年6月于蚌埠医学院第一附属医院明确诊断为CHF并应用沙库巴曲缬沙坦的患者99例，分别收集其应用沙库巴曲缬沙坦前及应用后3个月的血标本，检测治疗前后血CyPA、Galectin-3、MMP-2、MMP-9、NT-proBNP水平。  结果  CHF患者应用沙库巴曲缬沙坦后血CyPA、Galectin-3、MMP-2、MMP-9、NT-proBNP水平明显低于应用前CyPA:(7.75±3.18)ng/mL vs. (10.13±3.32)ng/mL；Galectin-3:(9.66±5.20)ng/mL vs. (16.74±3.18)ng/mL；MMP-2:(12.02±5.69)ng/mL vs. (18.40±8.41)ng/mL；MMP-9:(8.32±4.34)ng/mL vs. (11.45±4.51)ng/mL；NT-proBNP:(1 319.24±404.11)ng/mL vs. (4 187.48±1 967.92)ng/mL，均P < 0.01]。  结论  沙库巴曲缬沙坦能明显降低CHF患者血CyPA、Galectin-3、MMP-2、MMP-9、NT-proBNP水平，改善心功能，这可能对CHF的治疗效果评估有一定的作用。 

Influence of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure

  Objective  By measuring the levels of blood cyclophilin A (CyPA), galectin-3, matrix metalloproteinase-2(MMP-2), MMP-9, N-terminal B type natriuretic peptide (NT-proBNP) in patients with chronic heart failure (CHF) before and after the application of sacubitril/valsartan, the effects of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure were discussed.  Methods  We selected 99 cases with CHF treated with sacubitril/valsartan at the First Affiliated Hospital of Bengbu Medical College from December 2018 to June 2022. Blood samples were collected before and 3 months after treatment by sacubitril/valsartan, and the blood CyPA, galectin-3, MMP-2, MMP-9 and NT-proBNP levels before and after treatment by sacubitril/valsartan were compared.  Results  After treatment, the levels of blood CyPA, Galectin-3, MMP-2, MMP-9 and NT-proBNP in patients with CHF showed significant differences compared with those before treatment CyPA: (7.75±3.18) ng/mL vs. (10.13±3.32) ng/mL; Galectin-3: (9.66±5.20) ng/mL vs. (16.74±3.18) ng/mL; MMP-2: (12.02±5.69) ng/mL vs. (18.40±8.41) ng/mL; MMP-9: (8.32±4.34) ng/mL vs. (11.45±4.51)ng/mL; NT-proBNP: (1 319.24±404.11) ng/mL vs. (4 187.48±1 967.92) ng/mL, all P < 0.01].  Conclusion  Sacubitril/valsartan can significantly reduce the levels of blood CyPA, Galectin-3, MMP-2, MMP-9 and NT-proBNP in patients with CHF and improve cardiac function, which may have certain effects on the evaluation of treatment with CHF.